RESEARCH ARTICLE

ASSOCIATION BETWEEN PRIMARY SITE OF MELANOMA AND SURVIVAL OF U.S. ADULT PATIENTS

Algarni Ali ¹, Al-Omari Naïf⁴, Acuna Juan ² and Sami Aldaham¹.

1. Al Imam Mohammad Ibn Saud Islamic University (IMSIU), Saudi Arabia.
2. Florida International University (FIU), United States.

Manuscript Info

Abstract

Introduction: Melanoma is the most dangerous form of skin cancer. The National Cancer Institute estimated that there would be 76,100 new invasive melanoma cases and 9,710 deaths from melanoma in the US in 2014. Anatomic location was identified as a significant prognostic factor in patients with primary cutaneous melanoma (CM) by several investigators.

Objectives: The aim of this study is to assess the relationship between primary site of melanoma and survival in a large US adult population.

Materials & methods: We analyzed 227,509 US melanoma patients from the SEER (Surveillance, Epidemiology, and End Results Program Registry) from 1973 to 2011. We excluded duplicate cases. We compared the primary site and survival by using Kaplan-Meier curves. Hazard ratio (HR) were determined by unadjusted and adjusted Cox-regression model.

Results: In the unadjusted model, the primary anatomical site was significantly associated with survival. Melanoma patients who had a primary site as an overlapping lesion of skin (the tumor overlaps the boundaries of two or more adjacent anatomical sites) were 10 times more likely to die within 5 years of diagnosis compared to patients with non-overlapping lesions located on the head or neck (HR= 10.7, 95%CI=10.3 - 11.1). After we adjusted for age at diagnosis, gender, race, ethnicity and stage at diagnosis, patients with overlapping lesion of skin still had lower chance of surviving more than 5 years as compared to patients with non-overlapping head and neck lesions, followed by trunk (HR= 3.5, 95%CI= 3.3 - 3.6 and HR=1.2, 95%CI= 1.2 - 1.3, respectively).

Conclusions: Overlapping lesion of skin had the worst prognosis followed by trunk lesions, while lesions located at upper limbs & shoulders had better prognosis. Clinical correlation and timely diagnosis of primary melanoma sites might improve survival and prognosis in this population.

Copy Right, IJAR, 2016. All rights reserved.
Introduction:
Melanoma is the most dangerous form of skin cancer that represents 4.6% of all new cancer cases in the United States. The National Cancer Institute estimated that there would be 76,100 new invasive melanoma cases and 9,710 deaths from melanoma in the United States in 2014[1,2]. Anatomic location was identified as a significant prognostic factor in patients with primary cutaneous melanoma (CM) by several investigators.[3,4,5,6]. Understanding the role of anatomic site in melanoma survival is important for public health messages on skin awareness and sun protection. Moreover, because the role of screening in melanoma is considered important for early detection [7,8]. The location often has been classified into four anatomic regions: head and neck, trunk, and the upper and lower extremities [9,10,11,12]. But some authors have tried to subdivide anatomic location into higher and lower risk sites according to recurrence or survival rates [5,13,14,15]. Cutaneous head and neck melanomas (CHNM) constitute 12-21% of melanomas diagnosed annually [16,17]. CHNM have poorer outcomes relative to melanomas of other sites (MOS) [18,19,20]. Extremity lesions have generally been associated with a more favourable prognosis than trunk and head and neck lesions, even when adjusted for tumour type and thickness [21,22]. Other authors have confirmed that the anatomical location is a prognostic factor, but have demonstrated a poor prognosis in association with other areas, such as the BANS region (upper back, posterior arm, neck and posterior scalp) [23].

Objectives:
The aim of this study is to assess the relationship between primary site of melanoma and survival in a large US adult population.

Literature Review:
Warren H. Tseng et al argued that Tumor Location Predicts Survival in Cutaneous Head and Neck Melanoma. An analysis of the Surveillance Epidemiology and End Results (SEER) database of the National Cancer Institute of all patients with CHNM diagnosed from 1988 to 2006. Kaplan-Meier survival curves depicting overall survival (OS) and melanoma specific survival (MSS) dependent on location of tumor. Result shown that ten-year overall survival was 55.1% for all patients with cutaneous head and neck melanoma. For tumors of the scalp/neck, 10-year rates of overall survival was 57.2%. 10-year overall for cutaneous head and neck melanoma (CHNM) at sites other than the scalp/neck was 55.6%. The author concluded that Patients with melanomas of the scalp/neck have poorer OS and MSS and those with lip melanomas have poorer MSS. These anatomic areas should not be overlooked when performing skin examinations [24].

Claus Garbe, et al discussed Prognostic Classification of Anatomic Location of Primary Cutaneous Melanoma. In a series of 5093 patients with invasive primary cutaneous melanoma followed from 1970 to 1988 at four university centers in Germany who were investigated using the multivariate Cox proportional hazard model to analyze the importance of anatomic location for survival probability. The back and breast (thorax), upper arm, neck, and scalp (TANS regions) were identified as high risk sites as the univariate 10-year survival rates for primary CM showed significant site-related differences ranging from 63.4% (scalp), 68% (back) to 87.7% (lower arm), 82.4% (lower leg). The author concluded that the Anatomic location was confirmed as an independent prognostic factor for patients with primary cutaneous melanoma. The TANS regions were identified as high risk sites, and the lower trunk, thigh, lower leg, foot, lower arms, hands, and face were identified as intermediate sites [25].

H. M. SHAW, et al discussed Influence of Site of Lesion and Age of Patient in the Female Superiority in Survival. Statistical analyses of differences between survival rates were carried out by the Logrank method. Observed and expected differences were analyzed for significance by the chi-square test with one degree of freedom. final group comprised 753 patients (362 men and 391 women). Result showed that Melanoma of extremities had better prognosis than axial melanoma with 5-yr survival (<1.5mm thick) of 85.7% in men and 96.8 % in women, as opposed to axial melanoma 5-yr survival (<1.5mm thick) of 75.7% in men and 84.3% in women. The author concluded that The association between decline in prognosis with increasing age and decline in proportion of thin lesions with increasing age was much closer in men than women. In men and women matched by age, site, and thickness of primary lesions, women with very thick tumors still survived longer [26].

Material & Method:
In this study our population was 249175 US melanoma patients from the SEER (Surveillance, Epidemiology, and End Results Program Registry) during the 1973 to 2011 period. We excluded 20366 patients as duplicated cases and
1300 patients younger than 18 years old. The final group was 227509 US melanoma patients, we analyzed them using SPSS [Figure 1]. We used Kaplan-Meier curves to compare primary sites and survival with 5 years interval [Figure 2]. Hazard ratio (HR) were determined by unadjusted and adjusted Cox-regression model.

**Figure 1:** Selection of melanoma patient from SEER database 1973 - 2011

**Figure 2:** Kaplan Meier curve of survival time for adult melanoma patients in US (1973-2011)
Result and Discussion:
Patients with primary lesions located at trunk contributed the highest number of patients by 64457 followed by head and neck by 58138 Patients. Patients with Overlapping lesions were 14948 as the smallest group. [Figure 3]

The Mean Age of patients with primary site at Head & neck lesion are older (65.5) which is higher than other lesion. Men have higher percentage of overlapping lesion of skin and skin NOS (81.7%) while women contribute higher percentage of lower limb & hip lesion (70.4%). Most of melanoma patients are white (97.1%). Most of the melanoma patients are Non-Spanish-Hispanic-Latino (97.7%). Patients with overlapping lesion and Skin NOS diagnosed at late stage in contrast to other lesions. [Table 1]

Patients who survived 5 years or less are older (61.3) compare to those who survived more than 5 years. Patient with primary sites of melanoma located at lower limb/hip and trunk have higher percentage in more than 5 year category (63.9% and 63.5% respectively). While patients with primary site defined as overlapping lesion of skin and skin NOS have the lower percentage (26.5%) of surviving more than 5 years. Women diagnosed with melanoma have better higher percentage of surviving after 5 years compared with men (64.8% and 53.8% respectively). Patients diagnosed at early stage (63.7%) have more probability of surviving 5 years or more than those at late stage (36.3%). [Table 2]

In our unadjusted model the primary site was significantly associated with the survival. Melanoma patients whose primary site was overlapping lesion of skin/skin NOS are 10 times more likely to die due to melanoma compared to patients with lesions at head/neck (HR= 0.772). Women are 60% less likely to die from melanoma compared with men. Patients diagnosed at late stage are have worse prognosis in comparison to those diagnosed at early stage (HR= 11.229).

After we adjusted for age and stage at diagnosis, gender, race and ethnicity, overlapping lesion of skin/skin NOS and lower limb/hip were highly associated with unfavorable prognosis of melanoma compared to head/neck (HR= 3.500 and HR=1.900 respectively). Women are still less likely to die from melanoma compared with men (H=0.600). Patients who have the worst prognosis for melanoma are those diagnosed at late stage (HR=8.900) and white patients (HR=1.200). [Table 3]

Less than 10% of overlapping lesions patients survived 60 months. Around 43% of trunk and lower limbs and hip patients survived 60 months. Upper limb and shoulder and head and neck patients had the highest percentage of surviving 60 months by more than 50%. [Figure 4]
Table 1: Characteristics of melanoma patients by primary site in US, (SEER 1973-2011)

| Characteristics                  | Primary Site          | N (%) | N (%) | N (%) | N (%) | N (%) | Sig<sup>a</sup> |
|----------------------------------|-----------------------|-------|-------|-------|-------|-------|-----------------|
|                                  | Head & neck           | N (%) |       | Trunk |       |       |                 |
| Age at diagnosis in years (mean, SD)<sup>b</sup> | (65.5, ± 16.1)        | (53.9, ± 16.3) | (57.4, ± 16.5) | (52.7, ± 17.0) | (48.7, ± 17.3) | <0.001 |
| Gender                           |                       |       |       |       |       |       |                 |
| Male                             | 39237 (67.5)          | 41242 (64.0) | 24847 (49.7) | 11819 (29.6) | 12209 (81.7) | <0.001 |
| Female                           | 18901 (32.5)          | 23215 (36.0) | 25135 (50.3) | 28165 (70.4) | 2739 (18.3) |                 |
| Race                             |                       |       |       |       |       |       |                 |
| White                            | 55826 (98.2)          | 61330 (97.9) | 47689 (98.3) | 37194 (95.5) | 13251 (89.9) | <0.001 |
| Black                            | 375 (0.7)             | 630 (1.0) | 404 (0.8) | 1070 (2.7) | 1132 (7.7) | <0.001 |
| Other<sup>d</sup>                | 638 (1.1)             | 664 (1.1) | 483 (0.9) | 676 (1.7) | 362 (2.5) |                 |
| Ethnicity                        |                       |       |       |       |       |       |                 |
| Non-Spanish-Hispanic-Latino      | 57029 (98.1)          | 63329 (98.2) | 49076 (98.2) | 38732 (96.9) | 14002 (93.7) | <0.001 |
| Spanish-Hispanic-Latino          | 1109 (1.9)            | 1128 (1.8) | 906 (1.8) | 1252 (3.1) | 5341 (2.3) | <0.001 |
| Stage<sup>e</sup>               |                       |       |       |       |       |       |                 |
| Early                            | 50601 (91.3)          | 56228 (91.0) | 44099 (92.5) | 32301 (89.5) | 1378 (26.0) | <0.001 |
| Late                             | 4832 (8.7)            | 5558 (9.0) | 3552 (7.5) | 3771 (10.5) | 3912 (74.0) | <0.001 |
| Mortality                        |                       |       |       |       |       |       |                 |
| Alive or dead of other cause     | 43788 (90.2)          | 51522 (89.0) | 40660 (91.8) | 32094 (88.2) | 5099 (36.7) | <0.001 |
| Dead                             | 4778 (9.8)            | 6378 (11.0) | 3642 (8.2) | 4286 (11.8) | 8797 (63.3) |                 |

<sup>a</sup> P-value was calculated based on Chi-square unless otherwise specified  
<sup>b</sup> Significat of age was calculated based on ANOVA test  
<sup>c</sup> NOS: not otherwise specified  
<sup>d</sup> Other (Race): American Indian/AK Native, Asian/Pacific Islander  
<sup>e</sup> Satge has 9.4% missing

Table 2: Association between Survival and Age, Gender, Race, Ethnicity, Stage and mortality in melanoma patients

| Characteristics                  | Survival (years) | p-value<sup>a</sup> |
|----------------------------------|------------------|---------------------|
|                                  | ≤ 5 years | > 5 years |          |
|                                  | N (%)     | N (%)     |          |
| Age at diagnosis in years (mean, SD)<sup>b</sup> | (61.3, ± 17.8) | (54.1, ± 16.3) | < 0.001 |
| Primary site                     |              |          | < 0.001 |
| Head & Neck                      | 26287 (45.2) | 31851 (54.8) |          |
| Trunk                            | 23554 (36.5) | 40903 (63.5) |          |
| Upper limb & shoulder            | 19045 (38.1) | 30937 (61.9) |          |
| Lower limb & Hip                 | 14425 (36.1) | 25559 (63.9) |          |
| Overlapping lesion of skin & skin NOS<sup>c</sup> | 10983(73.5) | 3965(26.5) | < 0.001 |
| Gender                           |              |          |          |
Male | 59767 (46.2) | 69587 (53.8) | < 0.001
Female | 34527 (35.2) | 63628 (64.8) | < 0.001

### Race

| | < 0.001 |
|----------------|--------|
| White | 88527 (41.1) | 126763 (58.8) |
| Black | 2088 (57.8) | 1523 (42.2) |
| Other \(^c\) | 1268 (45.6) | 1510 (54.4) |

### Ethnicity

| | < 0.001 |
|----------------|--------|
| Non-Spanish-Hispanic-Latino | 91662 (41.3) | 130505 (58.7) |
| Spanish-Hispanic-Latino | 2632 (49.3) | 2709 (50.7) |

### Stages

| | < 0.001 |
|----------------|--------|
| Early | 67086 (36.3) | 117521 (63.7) |
| Late | 13770 (63.7) | 7855 (36.3) |

### Mortality

| | < 0.001 |
|----------------|--------|
| Alive or dead of other cause | 58171 (33.6) | 114992 (66.4) |
| Dead | 21164 (75.9) | 6717 (24.1) |

\(^d\) Other (Race): American Indian/AK Native, Asian/Pacific Islander

\(^a\) P-value was calculated based on Chi-square unless otherwise specified

\(^b\) Significant of age was calculated based on T test

\(^c\) NOS: not otherwise specified

---

**Table 3:** Unadjusted and Adjusted associations between hazard ratio and characteristics of melanoma patients

| Characteristics | Unadjusted | Adjusted |
|-----------------|------------|----------|
| | Survival (months) | HR (95% CI) | p-value | HR \(^a\) (95% CI) | p-value |
| Primary site | | | | | |
| Head & Neck | Ref | | | | |
| Trunk | 1.017 (0.979 -1.056) | 0.391 | 1.245 (1.193-1.298) | <0.001 |
| Upper limb & shoulder | 0.772 (0.739 - 0.806) | <0.001 | 0.906 (0.863-0.951) | <0.001 |
| Lower limb & Hip | 1.081 (1.037 - 1.126) | <0.001 | 1.196 (1.138-1.257) | <0.001 |
| Overlapping lesion of skin and skin NOS \(^c\) | 10.723 (10.347 - 11.112) | <0.001 | 3.507 (3.325-3.698) | <0.001 |
| Age at diagnosis in years | 0.999 (0.998 - 1.000) | 0.02 | 1.022 (1.021-1.023) | <0.001 |
| Gender | | | | | |
| Male | Ref | | | | |
| Female | 0.369 (0.386 - 0.407) | <0.001 | 0.671 (0.650-0.693) | <0.001 |
| Race | | | | | |
| White | Ref | | | | |
| Black | 0.274 (0.259 - 0.289) | <0.001 | 1.265 (1.108-1.445) | <0.001 |
| Other \(^c\) | 0.452 (0.408 - 0.500) | <0.001 | 1.100 (0.918-1.304) | 0.315 |
| Ethnicity | | | | | |
| Non-Spanish-Hispanic-Latino | 0.517 (0.487 - 0.548) | <0.001 | 0.952 (0.861-1.053) | 0.339 |
| Spanish-Hispanic-Latino | Ref | | | | |
| Stages | | | | | |
| Early | Ref | | | | |
| Late | 11.229 (10.902 -11.566) | <0.001 | 8.968 (8.687-9.258) | <0.001 |

\(^a\) HR: Hazard Ratio

\(^c\) NOS: not otherwise specified
Other (Race): American Indian/AK Native, Asian/Pacific Islander

Figure 4: Survival curve of primary sites (N=94294)

Conclusions:
This study have shown a very obvious difference in survival between the primary sites. Overlapping lesion of skin had the worst prognosis followed by trunk lesions while upper limb & shoulder lesions have a better prognosis. Timely diagnosis of primary melanoma sites will improve survival and prognosis of this population.

Acknowledgments:
We would like to thank Florida International University (FIU), Dr. Suliman Aba Al-Khail, Dr. Khalid Alquamaizi, Dr. Juan Zevallos, and Grettel Castro for their support and help.

References:
1. http://www.skincancer.org/skin-cancer-information/melanoma(accessed March 21, 2015).
2. http://www.seer.cancer.gov/statfacts/html/melan.html (accessed March 29, 2015)
3. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA, Halpern NB. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark’s and Breslow’s staging methods. *Ann Surg* 1978; 188:732-42.
4. Ringborg U, Afzelius LE, Lagerlof B, Adami HO, Augustsson I, Blomqvist E, et al. Cutaneous malignant melanoma of the head and neck. *Cancer* 1993; 71:751-8.
5. Clark WH Jr., Elder DE, Guerry D, Braintman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. *J Natl Cancer Inst* 1989; 81:1893-904.
6. Blois MS, Sagebiel RW, Tuttle MS, Caldwell TM, Taylor HW. Judging prognosis in malignant melanoma of the skin: a problem of inference over small data sets. *Ann Surg* 1983; 198:ZOO-6.
7. Geller AC, Miller DR, Swetter SM, Demierre MF, Gilchrest BA. A call for the development and implementation of a targeted national melanoma screening program. *Arch Dermatol*. 2006;142(4):504-507.
8. Koh HK. Melanoma screening: focusing the public health journey. *Arch Dermatol*. 2007;143(1):101-103.
9. Sondergaard K, Schou G. Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases. *Virchows Arch Pathol Anat* 1985;406:179-95.
10. Vossaert KA, Silverman MK, Kopf AW, Bart RS, Rigel DS, Friedman RJ, et al. Influence of gender on survival in patients with stageI malignant melanoma. *J Am Acad Dermatol* 1992;26:429-40.
11. Balch CM, Soong SJ, Shaw HM, Milton GW. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, editors. Cutaneous melanoma: clinical management and treatment outcomes worldwide. Philadelphia: JB Lippincott, 1992: 165-87.
12. O'Doherty CJ, Prescott RJ, White H, McIntire M, Hunter JAA. Sex differences in presentation of cutaneous malignant melanoma and survival from stage I disease. Cancer 1986; 58:788-92.
13. Day CL Jr, Mihm MC Jr, Sober AJ, Harris MN, Kopf AW, Fitzpatrick TB, et al. Prognostic factors for melanoma patients with lesions 0.76-1.69 mm in thickness: an appraisal of "thin" level IV lesions. Ann Surg 1982; 195:30-4.
14. Rogers GS, Kopf AW, Rigel DS, Friedman JL, Levine JL, Levenstein ML, et al. Effect of anatomical location on prognosis in patients with clinical stage I melanoma. Arch Dermatol 1983; 119:644-9.
15. Luria LW, Proper SA, Burnett SM, Williams CC, Fenske N. An anatomical basis for prognosis of malignant melanoma. Plast Reconstr Surg 1992; 90:2639.
16. Golger A, Young DS, Ghazarian D, Neligan PC. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study. Arch Otolaryngol Head Neck Surg 2007; 133(5):442-7. [PubMed: 17515502]
17. Hoersch B, Leiter U, Garbe C. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol. 2006; 155(4):771-7. [PubMed: 16965427]
18. Gillgren P, Mansson-Brahme E, Frisell J, Johansson H, Larsson O, Ringborg U. A prospective population-based study of cutaneous malignant melanoma of the head and neck. Laryngoscope. 2000; 110(9):1498-504. [PubMed: 10983950]
19. Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol. 2008; 144(4):515-21. [PubMed: 18427046]
20. Balch CM, Soong SJ, Milton GW, et al. A comparison of prognostic factors and surgical outcomes in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg. 1982;196(6):677-84. [PubMed: 7149819]
21. Blois MS, Sagebiel RW, Abarbanel RM, Caldwell TM, Tuttle MS. Malignant melanoma of the skin. I. The association of tumor depth and type, and patient sex, age, and site with survival. Cancer 1983; 52:1330-1341.
22. Day CL Jr, Mihm MC, Lew RA, Harris MN, Kopf AW, Fitzpatrick TB, et al. A multivariate analysis of prognostic factors for melanoma patients with lesions > 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg 1982; 195:44-49.
23. Day CL, Mihm MC, Sober AJ, Lew RA, Harris MN, Kopf AW, et al. Prognostic factors for melanoma patients with lesions 0.76-1.69 mm thickness. An appraisal of ‘thin’ level IV lesions. Ann Surg 1982; 195:30-34.
24. Warren H, Tseng, et al. Tumor Location Predicts Survival in Cutaneous Head and Neck Melanoma. J Surg Res. 2011; 167:192-8.
25. Claus Garbe, et al. Primary Cutaneous Melanoma Prognostic Classification of Anatomic Location. Cancer. 1995; 75:2492-8.
26. H.M. SHAW, et al. Malignant Melanoma: Influence of Site of Lesion and Age of Patient in the Female Superiority in Survival. Cancer. 1980; 46:2731-5.